UY32189A - Ligandos que tienen esepecificidad de unión por dc-sign - Google Patents

Ligandos que tienen esepecificidad de unión por dc-sign

Info

Publication number
UY32189A
UY32189A UY0001032189A UY32189A UY32189A UY 32189 A UY32189 A UY 32189A UY 0001032189 A UY0001032189 A UY 0001032189A UY 32189 A UY32189 A UY 32189A UY 32189 A UY32189 A UY 32189A
Authority
UY
Uruguay
Prior art keywords
sign
immunoglobulins
compositions
esepecificity
ligandos
Prior art date
Application number
UY0001032189A
Other languages
English (en)
Spanish (es)
Inventor
Rudolf Mari De Wildt
Original Assignee
Domantis Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Domantis Ltd filed Critical Domantis Ltd
Publication of UY32189A publication Critical patent/UY32189A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2851—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the lectin superfamily, e.g. CD23, CD72
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Biomedical Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Physics & Mathematics (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Plant Pathology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Microbiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
UY0001032189A 2008-10-21 2009-10-20 Ligandos que tienen esepecificidad de unión por dc-sign UY32189A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US10708508P 2008-10-21 2008-10-21

Publications (1)

Publication Number Publication Date
UY32189A true UY32189A (es) 2010-05-31

Family

ID=42062429

Family Applications (1)

Application Number Title Priority Date Filing Date
UY0001032189A UY32189A (es) 2008-10-21 2009-10-20 Ligandos que tienen esepecificidad de unión por dc-sign

Country Status (16)

Country Link
US (1) US20110257373A1 (enExample)
EP (1) EP2356149A2 (enExample)
JP (1) JP2012506237A (enExample)
KR (1) KR20110071139A (enExample)
CN (1) CN102257009A (enExample)
AR (1) AR073905A1 (enExample)
AU (1) AU2009306424A1 (enExample)
BR (1) BRPI0919714A2 (enExample)
CA (1) CA2740856A1 (enExample)
EA (1) EA201100488A1 (enExample)
IL (1) IL212086A0 (enExample)
MX (1) MX2011004244A (enExample)
TW (1) TW201019962A (enExample)
UY (1) UY32189A (enExample)
WO (1) WO2010046337A2 (enExample)
ZA (1) ZA201102763B (enExample)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2009306425B2 (en) * 2008-10-21 2013-09-12 Domantis Limited Composition for targeting dendritic cells
WO2013095973A1 (en) * 2011-12-19 2013-06-27 The Rockefeller University Hdc-sign binding peptides
US20250319024A1 (en) * 2021-08-27 2025-10-16 University Of Georgia Research Foundation, Inc. Targeted nanoparticles and their uses related to infectious disease
CN118184795B (zh) * 2022-12-13 2025-03-21 成都维瑾柏鳌生物医药科技有限公司 抗hiv-1的重组蛋白及其应用

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0598108A1 (en) * 1992-06-05 1994-05-25 Dade Produktions AG Rabbit single domain antibody and use thereof
EP2284192A3 (en) * 2002-11-08 2011-07-20 Ablynx N.V. Camelidae antibodies for sublingual administration
RU2357974C2 (ru) * 2003-01-10 2009-06-10 Аблинкс Н.В. Терапевтические полипептиды, их гомологи, их фрагменты и их применение для модуляции агрегации, опосредованной тромбоцитами
JP4889493B2 (ja) * 2003-05-14 2012-03-07 ドマンティス リミテッド ポリペプチドレパートリーから可逆的にアンフォールドするポリペプチドを回収するための方法
ES2315664T3 (es) * 2003-06-30 2009-04-01 Domantis Limited Anticuerpos de dominio unico (dab) pegilados.
JP4970035B2 (ja) * 2003-08-21 2012-07-04 リポテック・プロプライエタリー・リミテッド ｉｎｖｉｖｏにおける樹状細胞の標的化
CA2569240A1 (en) * 2004-06-01 2005-12-15 Domantis Limited Drug fusion comprising a polypeptide drug and an immunoglobulin heavy chain variable domain specific for serum albumin
JP2008521870A (ja) * 2004-12-02 2008-06-26 ドマンティス リミテッド 抗ｉｌ−１ｒ１単一ドメイン抗体および治療使用
WO2006059106A2 (en) * 2004-12-02 2006-06-08 Domantis Limited Bispecific domain antibodies targeting serum albumin and glp-1 or pyy
KR20080003351A (ko) * 2005-03-18 2008-01-07 도만티스 리미티드 캔디다 항원에 대한 항체
US20100056439A1 (en) * 2005-12-06 2010-03-04 Domantis Limited Ligands that have binding specificity for egfr and/or vegf and methods of use therefor
CA2632424A1 (en) * 2005-12-06 2007-06-14 Domantis Limited Bispecific ligands with binding specificity to cell surface targets and methods of use therefor
TW200804593A (en) * 2006-01-24 2008-01-16 Domantis Ltd Fusion proteins that contain natural junctions
WO2008039432A1 (en) * 2006-09-26 2008-04-03 Alexion Pharmaceuticals, Inc. Compositions and methods for enhancing an adjuvant
WO2008070363A2 (en) * 2006-10-31 2008-06-12 Domantis Limited Intrabodies
CN101182539A (zh) * 2007-11-06 2008-05-21 浙江大学 Dc-sign启动子荧光素酶报告质粒的构建方法

Also Published As

Publication number Publication date
EA201100488A1 (ru) 2011-12-30
MX2011004244A (es) 2011-05-25
CN102257009A (zh) 2011-11-23
BRPI0919714A2 (pt) 2015-12-08
KR20110071139A (ko) 2011-06-28
IL212086A0 (en) 2011-06-30
US20110257373A1 (en) 2011-10-20
CA2740856A1 (en) 2010-04-29
WO2010046337A2 (en) 2010-04-29
ZA201102763B (en) 2012-09-26
JP2012506237A (ja) 2012-03-15
WO2010046337A3 (en) 2010-07-01
AR073905A1 (es) 2010-12-09
EP2356149A2 (en) 2011-08-17
TW201019962A (en) 2010-06-01
AU2009306424A1 (en) 2010-04-29

Similar Documents

Publication Publication Date Title
CL2015001507A1 (es) Proteínas de unión al antígeno bcma
ZA202308846B (en) Cx3cr1-binding polypeptides
IL275114B (en) Antibody constructs for cdh19 and cd3 binding sites, preparations containing them, methods for their preparation and uses thereof
CY1121560T1 (el) Ανοσογονικη συνθεση
UA116632C2 (uk) Химерний білок, який містить фактор viii та фактор віллебранда, і його застосування
BR112014023415A2 (pt) moléculas que se ligam a ang2
CR9969A (es) Anticuerpos anti-globulomero ab, porciones de union a antigeno de estos, hibridomas correspondientes, acidos nucleicos, vectores, celulas huesped, metodos para producir dichos anticuerpos, composiciones que comprenden dichos anticuerpos
UA114707C2 (uk) БІСПЕЦИФІЧНА ЗВ'ЯЗУВАЛЬНА МОЛЕКУЛА, ЯКА ЗВ'ЯЗУЄТЬСЯ З VEGF I Ang2
MX350962B (es) Metodo para fabricar moleculas heterodimericas de fragmentos cristalizables de anticuerpo, utilizando efectos electrostaticos de direccion.
DOP2014000029A (es) Proteínas y péptidos modificados.
JOP20170027B1 (ar) بنيات جسم مضاد مشتبك بخلية t ثنائي الانتقائية لـ bcma وcd3
EA201791744A2 (ru) Улучшенная липидная композиция
CO6351750A2 (es) Composiciones y métodos para anticuerpos que se dirigen a la proteina de complementos c5
BR112014019611A2 (pt) agentes de ligação mica
BR112014028645A2 (pt) composições e métodos para modulação da expressão de apoa1 e abca1.
RU2014136702A (ru) Одноцепочечные антитела и другие гетеромультимеры
IN2012DN00640A (enExample)
IL211394B (en) Chimeric fusion proteins for inducing an immune response to p. gingivalis, preparations containing them and their uses
BR112012023015A2 (pt) imunoensaios para lenalidomida e talidomida
WO2011086143A3 (en) Liver targeting domain antibodies
MX2013008702A (es) Composiciones que contienen anticuerpos glicosilados y sus usos.
WO2012009544A3 (en) Domain insertion immunoglobulin
EA201590887A1 (ru) Композиция
UY32189A (es) Ligandos que tienen esepecificidad de unión por dc-sign
EA201200545A1 (ru) Производные пиразола, которые модулируют стеароил-соа десатуразу